3 results
Approved WMOCompleted
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
Approved WMOPending
Primary objective:• To evaluate biodistribution of 89Zr-atezolizumab in patients with high risk DLBCL at diagnosis.Secondary objective:• To assess the heterogeneity of 89Zr-atezolizumab tumor uptake in high-risk DLBCL before R-CHOP.• To correlate…
Approved WMOPending
The primary objective of the study is to assess the pharmacokinetics (PK) of PXL770 in AMN subjects at the dose of 500mg once daily (OD) and 250mg twice daily (BID) after 4 weeks of treatment.